Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
International Ballroom North (Lobby Level)
720 S Michigan Avenue
Chicago, IL 60605
The significance of deficiencies in mismatch repair (dMMR) pathways and microsatellite instability (MSI) toward the delivery of precision cancer care is evolving. Mismatch repair deficiencies and MSI are important components in the pathogenesis of certain solid tumors that carry both prognostic and predictive value. Results from clinical studies suggest that a variety of solid tumors that are dMMR/MSI-high (MSI-H) phenotype respond to immune checkpoint inhibition more than MMR-proficient tumors, and have prompted further studies in this area. Additionally, results of ongoing research may lead to use of dMMR/MSI testing to predict response to immunotherapy across tumor types. These investigations have the potential to impact a broad number of solid tumor types, with immunotherapy being delivered based on genetic composition (ie, MSI-H) versus tumor type. New Frontiers in Immuno-Oncology for Microsatellite-Instability-High Cancers is a CME-certified, live symposium to be held adjunct to an annual oncology meeting in Chicago, Illinois. We invite you to join a renowned group of experts in the treatment of MSI-H tumors as they guide participants through this fascinating and potentially practice-transforming application of immunotherapy.
Key topics on the agenda include:
This educational activity is directed toward medical oncologists who treat patients with solid tumors. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of solid tumors also are invited to participate.
Upon completion of this activity, participants should be better prepared to:
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018